Table 1.
Baseline Characteristics (Modified Intention-to-Treat Population)a
| Characteristic | Secnidazole 2 g (n = 64) |
Placebo (n = 67) |
Overall (N = 131) |
|---|---|---|---|
| Age, y | |||
| Mean (SD) | 36.9 (11.3) | 38.4 (11.12) | 37.7 (11.19) |
| Median (range) | 34.5 (19–65) | 39.0 (15–65) | 36.0 (15–65) |
| Race, No. (%) | |||
| American Indian/Alaska Native | 1 (1.6) | 1 (1.5) | 2 (1.5) |
| Asian | 1 (1.6) | 0 | 1 (0.8) |
| Black/African American | 59 (92.2) | 60 (89.6) | 119 (90.8) |
| Native Hawaiian/Other Pacific Islander | 0 | 0 | 0 |
| White | 3 (4.7) | 6 (9.0) | 9 (6.9) |
| Other | 0 | 0 | 0 |
| Ethnicity, No. (%) | |||
| Not Hispanic or Latino | 62 (96.9) | 65 (97.0) | 127 (96.9) |
| Hispanic or Latino | 2 (3.1) | 2 (3.0) | 4 (3.1) |
| Weight, kg, mean ± SD | 90.4 (25.9) | 92.4 (26.7) | 91.4 (26.3) |
| Weight, kg, median (range) | 87.1 (45.4–167.8) | 86.2 (49.9–180.5) | 86.6 (49.9–180.5) |
| BMI, kg/m2, mean ± SD | 33.8 (9.4) | 34.1 (9.3) | 34.0 (9.3) |
| BMI, kg/m2, median (range) | 32.2 (17.7–63.5) | 31.2 (19.5–62.3) | 31.6 (17.7–63.5) |
| Trichomoniasis symptomsb, No. (%) | |||
| Present | 56 (87.5) | 55 (82.1) | 111 (84.7) |
| Absent | 8 (12.5) | 12 (17.9) | 20 (15.3) |
| Bacterial vaginosis, No. (%) | 21 (32.8) | 17 (25.4) | 38 (29.0) |
| HIV positive, No. (%) | 5 (7.8) | 4 (6.0) | 9 (6.9) |
Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; SD, standard deviation.
aData are means ± SDs or n (%), unless otherwise specified.
bVaginal itching, discharge, and/or odor.